Effect of verapamil on urinary stone-forming risk factors

Urological Research

Volumn 35, Issue 1, 2007, Pages 23-27

  Sarica, Kemal ^a   Erturhan, Sakip ^b   Altay, Bulent ^a  

^a MEMORIAL HOSPITAL   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Calcium oxalate urolithiasis; Risk factors; Verapamil

Indexed keywords

CALCIUM; CITRIC ACID; OXALIC ACID; URIC ACID; VERAPAMIL;

ADULT; ARTICLE; CALCIUM OXALATE STONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; URINARY EXCRETION; URINARY TRACT INFECTION; UROLITHIASIS;

ADULT; CALCIUM CHANNEL BLOCKERS; CITRATES; FEMALE; HUMANS; HYPEROXALURIA; MALE; MIDDLE AGED; OXALATES; RECURRENCE; RISK FACTORS; TIME FACTORS; URINARY CALCULI; VERAPAMIL;

EID: 33846977743     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-006-0075-z     Document Type: Article

References (27)

1. Tiselius HG (2000) Metabolic evaluation and therapy. Curr Opin Urol 10(6):545-549
2. Pearle MS (2001) Prevention of nephrolithiasis. Curr Opin Nephrol Hypertens 10(2):203-209
3. Siener R, Glatz S, Nicolay C, Hesse A (2003) Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. Eur Urol 44(4):467-474
4. Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G (1999) A prospective study of recurrence rate and risk factors for recurrence after a Wrst renal stone. J Urol 162(1):27-30
5. Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A (1993) Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 155(3):839-843
6. Tekin A, Tekgul S, Atsu N, Bakkaloglu M, Kendi S (2002) Oral potassium citrate treatment for idiopathic hypocitruria in children with calcium urolithiasis. J Urol 168(6):2572-2574
7. Sarica K, Erturhan S, Yurtseven C, Yagci F (2006) The effect of potassium citrate therapy on stone recurrence and regrowth after ESWL in children. J Endourol (in press)
8. Cicerello E, Merlo F, Gambaro G, Maccatrozzo L, Fandella A, Baggio B, Anselmo G (1994) Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol 151(1):5-9
9. Epstein M (2002) Calcium antagonists in the mamagement of hypertension. In: Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 293-313
10. Goaling P (1986) Analytical reviews in clinical biochemistry: calcium measurement. Ann Clin Bichem 23:146
11. Krieg M, Gunsser KJ, Steinhagen-Tessen E, Becker H (1986) Comparative quantitative clinico-chemical analyses of the characteristics of 24-hour urine and morning urine. J Clin Chem Clin Biochem 24:863
12. Frishman WH (1994) Current status of calcium channel blockers. Curr Probl Cardiol 19:637-688
13. Epstein M (1992) Calcium antagonists and renal protection: current status and future perspectives. Arch Intern Med 152:1573-1584
14. Epstein M (2002) Calcium antagonists and the kidney: implications for renal protection. In: Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 629-664
15. Sarica K, Bakir K, Yagci F, Topcu O, Akbay C, Sayin N, Korkmaz C (1999) Limitation of shockwave-induced enhanced crystal deposition in traumatized tissue by verapamil in rabbit model. J Endourol 13(5):343-347
16. Gambaro G, Cicerello E, Marchini F, Paleari C, Borsatti A, Baggio B (1987) Are calcium antagonists potential antilithiasic drugs? Contrib Nephrol 58:181-183
17. Iguchi M, Ikegami M, Kiwamoto H, Umekawa T, Ishikawa Y, Kohri K, Kurita T (1993) Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers. Hinyokika Kiyo 39(5):425-431
18. Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A (1986) Effect of nifedipine on urinary calcium and oxalate excretion in renal stone formers. Nephron 43(3):234-235
19. Sarica K, Inal Y, Erturhan S, Yagci F (2006) The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. Urol Res 34(3):184-189
20. Carmines PK, Fowler BC, Bell PD (1993) Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol 265(5 Pt 2):677-685
21. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T (1996) Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 19(1):31-36
22. Grossman E, Messerli FH (1998) Effect of calcium antagonists on sympathetic activity. Eur Heart J 19(Suppl F):F27-F31
23. Mason RP, Marche P, Hintze TH (2003) Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 23(12):2155-2163
24. Bichler KH, Strohmaier WL, Schanz F, Nelde HJ, Gaiser I, Schulze E (1985) Effect of calcium antagonists (nifedipine) on nephrocalcinosis and calcium excretion in the rat. Urol Int 40(1):13-21
25. Jan CR, Chen WC, Wu SN, Tseng CJ (1998) Nifedipine, verapamil and diltiazem block shock-wave-induced rises in cytosolic calcium in MDCK cells. Chin J Physiol 41(4):181-188
26. Tanaka T, Nangaku M, Miyata T, Inagi R, Ohse T, Ingelfinger JR, Fujita T (2004) Blockade of calcium influx through L-type calcium channels attenuates mitochondrial injury and apoptosis in hypoxic renal tubular cells. J Am Soc Nephrol 15(9):2320-2333
27. Ogawa Y, Hayashi K, Nakahama T, et al (2001) Role of T-type calcium channels in renal microcirculation: studies in the isolated perfused hydronephrotic kidney. Hypertension 38:343-347